In the present study, we proposed a model-based methodology for the selection of an optimal repertoire of events for a composite endpoint, based on a meta-regression of historical data of anti-hypercholesterolemia therapies, including statins as well as anti-PCSK9 mAbs and siRNA. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.